Français Japonais Chinois Allemand Néerlandais Espagnol Portugais

    News

    Giroptic makes a splash with Facebook

    At Facebook’s annual conference in California, an enthusiastic Mark Zuckerberg gave a Giroptic iO camera to every attendee—and wrote a $1 million check to the Lille-based start-up.

    Arcelor Mittal Dunkerque investing in performance

    Steelmaker earmarks €31 million for continuous hot mill at Dunkerque plant.

    All news

    New biopharma start-up at Lille's Institut Pasteur

    10 Aug 2016 | Health Nutrition, A region on the move

    A revolutionary start-up has just seen the light of day at the Institut Pasteur campus in Lille. Immune InsighT is a biotech business specialized in analyses to confirm new drug candidates are safe. The company harnesses rare expertise to offer a unique services to clients around the world.

    Immune InsighT at Lille's Institut Pasteur

    Lille's Institut Pasteur is an international pace-setter and a key player in medical research. Over the past fifteen years, a dozen start-ups have been set up on its campus or through its research teams—including Immune InsighT in 2016.

    Immune InsighT offers an all-new, high-end method for confirming the safety of new drug candidates designed to treat cancer, transplants, auto-immune system and inflammatory illnesses, and applications in agrifood and the cosmetic industry prior to the launch of clinical tests. This fast-moving young company offers unique services worldwide.

    Completing the full range of tests offered by Immune InsighT early on enables client companies to identify the undesirable effects of drug candidates or other molecules on the immune system both reliably and quickly—and to anticipate the potential failure of a long and costly clinical trial well in advance. 

     

    Source: Lille's Institut Pasteur

    Back to news